Investigating how well a COVID-19 vaccine works in people with HIV
Official title: SARS-CoV-2 vaccine durability during SIV infection
Funded at University of Washington · NIH-10894621 · Data updated 2026-11-12
This study is looking at how well a new COVID-19 vaccine works for people living with HIV, especially those with weakened immune systems, to see if it can help them build strong protection against the virus.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $353,000 |
| NIH project number | 5R21AI170094-02 |
| Project ID | NIH-10894621 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals living with HIV, particularly those who are immunosuppressed or have untreated infections.
✕Less likely to help
Patients who are not living with HIV or those who are fully immunocompetent may not benefit from this research.
What this research studies
This research focuses on understanding the durability and effectiveness of a COVID-19 vaccine in individuals who are infected with HIV, particularly those who are immunosuppressed or untreated. The study uses a novel vaccine candidate that has shown promise in preclinical models, aiming to generate strong immunity against COVID-19 in these vulnerable populations. By utilizing advanced delivery methods, the research seeks to improve vaccine responses in patients who typically have weaker immune systems. The findings could help inform vaccination strategies in regions with high HIV prevalence.
Why it matters
Potential benefit: If successful, this research could lead to more effective COVID-19 vaccination strategies for individuals living with HIV, enhancing their protection against the virus.
How similar studies have gone: Other research has shown promise in using innovative vaccine platforms for immunocompromised populations, suggesting potential success for this approach.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: O'connor, Megan a — University of Washington
- Study coordinator: O'connor, Megan a
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.